Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Alaunos Therapeutics (TCRT) Invested Capital (2016 - 2025)

Historic Invested Capital for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to $2.8 million.

  • Alaunos Therapeutics' Invested Capital rose 290.01% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 290.01%. This contributed to the annual value of $2.1 million for FY2024, which is 6670.37% down from last year.
  • Latest data reveals that Alaunos Therapeutics reported Invested Capital of $2.8 million as of Q3 2025, which was up 290.01% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Alaunos Therapeutics' Invested Capital ranged from a high of $105.6 million in Q1 2021 and a low of $1.1 million during Q1 2025
  • Its 5-year average for Invested Capital is $37.9 million, with a median of $21.6 million in 2023.
  • Its Invested Capital has fluctuated over the past 5 years, first tumbled by 8859.91% in 2023, then skyrocketed by 290.01% in 2025.
  • Alaunos Therapeutics' Invested Capital (Quarter) stood at $82.2 million in 2021, then tumbled by 32.68% to $55.3 million in 2022, then plummeted by 88.6% to $6.3 million in 2023, then tumbled by 66.7% to $2.1 million in 2024, then soared by 33.48% to $2.8 million in 2025.
  • Its Invested Capital was $2.8 million in Q3 2025, compared to $3.7 million in Q2 2025 and $1.1 million in Q1 2025.